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BACKGROUND: One hypothesis has posited whether
abnormal lipid metabolism might be a causal factor in
the pathogenesis of osteoarthritis (OA). Routine statin
use in clinical practice provides the basis for a natural
experiment in testing this hypothesis.
OBJECTIVE: To test the hypothesis that statins reduce
the long-term occurrence of clinically defined OA.
DESIGN: Cohort design with a 10-year follow-up.
PARTICIPANTS: 16,609 adults cardiovascular disease
cohorts aged 40 years and over from the UK General
Practice Research Database with data available to 31
December 2006.
INTERVENTION: Statins were summarised as annual
mean daily dose and dose change over two-year time
periods.
MAIN MEASURES: Incident episode of clinically defined
osteoarthritis was assessed within 2 years, and at 4-
year and 10-year follow-up time periods, using Cox and
discrete time survival analysis. Covariates included age,
gender, deprivation, body mass index, cholesterol level,
pain-modifying drug co-therapies, and duration and
severity of cardiovascular disease.
KEY RESULTS: Higher therapeutic dose of statin, with a
treatment duration of at least 2 years was associated with
a significant reduction in clinical OA compared to non-
statin users in the follow-up time period. The estimated
adjusted rate ratios were as follows: lowest statin dose
quartile 1: 2.5 (95 % CI 2.3, 2.9); quartile 2: 1.3 (1.1, 1.5);
quartile 3: 0.8 (0.7, 0.95); and highest statin dose quartile
4: 0.4 (0.3, 0.5). The largest statin dose increments were
associated with significant reductions estimated at 18 %
in OA outcome within 2 years and 40 % after 4 years,
compared to non-statin users.
CONCLUSIONS: This longitudinal study from a national
clinical practice setting provides evidence that higher statin
dose and larger statin dose increments were associatedwith
a reduction in clinically defined OA outcome.
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BACKGROUND
Osteoarthritis (OA) is a complex disease that encompasses
change in articular, bone and cartilage structures.1 Current
clinical and research focus has been modification of mechan-
ical loading as a causal factor, or treatment of psychosocial
factors, or treatment and replacement of intra-articular
cartilage.2 Yet, studies of generalised osteoarthritis suggest
the potential role of systemic processes,3,4 and from this
framework, it has been hypothesised that disorder of lipid
metabolism may play a role in the pathogenesis of osteoar-
thritis.5,6 The hypothesis is generated from different evidence
in the cellular and bio-molecular pathways. First, adipocytes
share mesenchymal origin with articular cells, providing a
potential cellular link between lipid metabolism and osteoar-
thritis.7,8 Second, in vitro studies have shown that excessive
lipid levels in the synovial fluid induce arthritic changes, and
higher levels of leptin found in obesity has also been shown in
joint cartilage destruction.9,10 Supporting epidemiological
studies indicate that these two chronic diseases commonly
co-occur,11 share similar risk factors,12,13 and are both
associated with higher mortality.14
Recent literature suggests that statins may have a modifying
role in osteoarthritis.15 Our previous work has shown that the
risk factors for cardiovascular disease are also associated with
OA over a 30 year time period of follow-up,16 and smaller
studies have established “proof of principle” for such a link, in
radiographically confirmed subgroups of OA.17,18 However,
the full public health potential of statins remains to be
investigated, as well as whether there is an association with
the larger group presenting with clinical OA. For populations
at risk, statins are a key drug preventative therapy and form the
basis of quality care guidelines to prevent long-term cardio-
vascular events.19 The objective of this study was to use large
data sets available from the primary care population, where
OA is a common presenting problem and statin use is routine,
for investigating the hypothesis of whether statins are
associated with a reduction in OA occurrence.
METHODS
We used the General Practice Research Database (GPRD)
on over 300 practices, which links clinical diagnosis to
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other data, such as prescribed drugs, test results and
measurements such as body mass index (BMI). The
GPRD is representative of England and Wales population,
since most people are registered with a General Practitioner
(GP), and such data on a large scale population over a
longitudinal time period provides the basis for a variety of
hypothesis-testing epidemiological studies.20,21 All data is
routinely computer recorded, with diagnostic data coded as
patients present their clinical complaints, using a standard
clinical classification to record chronic diseases such as
cardiovascular disease and osteoarthritis.22 Permission to
access the GPRD data was given by the Independent
Scientific Advisory Committee.
Selection of Cohort Population
Cardiovascular disease (CVD) cohort populations aged
40 years and over were identified on the basis of a 2-year
time period (1 January 1995 to 31 December 1996) with no
clinical record of OA during this time period and in any
available patient records in the preceding time period. This
cohort (n=16,609) had linked records to drugs prescribed
and to any incident clinically defined OA outcome in the
following 10-year time period (1 January 1997 to 31
December 2006).
Within the overall cohort, there were six exclusive
subgroups of CVD, ordered as follows: (1) hypertension,
(2) atrial fibrillation, (3) angina, (4) myocardial infarction
and (5) heart failure. Groups were allocated to the most
‘severe’ diagnostic category, irrespective of other CVD
multimorbidity; for example, if a patient has heart failure
and hypertension, then they were allocated to the heart
failure cohort group. The sixth group consisted of any
‘other’ CVD symptoms and morbidities outside of the five
specific categories. This broader ‘other CVD’ cohort, with
some aspect of vascular disorders in their clinical records,
was chosen to provide validation for the specific diagnostic
groups.
Measures of Statin Use
Within the overall cohort, prescribed drugs had been coded
using the standard British National Formulary (BNF)
classification.23 Lipid-regulating drugs within this classifi-
cation were used to categorise statin users and other statins
were standardised to the equivalent Simvastatin dose.24
Statin dose was then summarised as the mean daily dose in
each 12-month time period, which equates to the prescrip-
tion dose x frequency of daily dose x quantity of tablets,
divided by 365 days. This process was done for the each of
the total 12 years of observation. For the overall cohort,
data was organised into statin users, and non-users were
classified on the basis of the whole of the 12-year time
period.
Clinically Defined OA Outcome
In the 10-year follow-up period, the incident outcome of “OA”
was defined on the basis of any coded clinical entry
irrespective of joint site, and there were 147 OA-related
diagnostic categories from a standard clinical classification.22
OA diagnoses were recorded by GPs in the actual consulta-
tions, when it was the primary presenting problem care. These
diagnostic codes focus on the specific use of the term
“osteoarthritis”, and not diffuse pain complaints or syndromes.
Previously, we have shown that these OA categories are a
marker of health severity, representing distinct diagnostic
application when OA is established.25 These clinical defini-
tions represent a different measure from radiographic defini-
tions of OA, but they are an important epidemiological clinical
measure in large general populations consulting over time,26,27
which provides the setting for an a priori natural experiment.
Current evidence also shows that OA can be viewed primarily
as a clinical joint pain syndrome, since clinical and radio-
graphic features are not always concordant.28,29
Other Factors
Duration of each CVD in years was also estimated on the basis
of time between the age at first diagnosis and the date of
diagnosis in the cohort sampling window, and was used as a
proxy marker of the ‘immortal’ time in which an OA event
might have occurred.30 Other measures included serum choles-
terol levels (mmol/l) and obesity, as summarised by BMI (kg/
m2).We used the first recorded cholesterol level or a BMI record
for an individual as a measure of baseline status, and repeated
measures were not used in analyses, because this type of data
was not fully available over the follow-up time period.
We also wanted to consider the potential role of other pain-
modifying drug co-therapies, such as analgesia (non-opioids,
opioids and non-steroidal anti-inflammatories) and anti-de-
pressants, which might be associated with a reduction in OA
presentation.31 These drug co-therapies based on BNF
classification were summarised into either analgesia users or
non-users in the six 2-year time periods for the whole period of
observation. Deprivation was measured by the Index of
Multiple Deprivation (IMD) for each practice, and was based
on the 2004 UK census and is an area-level measure of
deprivation. IMD is based on the postcode, and is a weighted
score of seven sub-domains relating to income; employment;
health; education, skills and training; barriers to housing, and
access to local services; crime; and living environment.32
STATISTICAL ANALYSIS
Modelling Statin Dose and Latency Period
In terms of hypothesising the time that it might take for a
person to be on statin to reduce the clinical occurrence of OA
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(potential ‘latency’ treatment time period), we estimated that a
minimum time period of 2 years of statin use was required.
This hypothetical time period for ‘treatment effect’ is based on
evidence from other studies, which show this is the duration of
statin use required in order to achieve a significant reduction in
cardiovascular disease outcomes.33,34
The statin daily dose measure was modelled in two ways.
In the overall cohort Cox regression analysis, statins were
defined as mean daily dose per year, to categorise statin
users of more than 2 years in the 10-year follow-up period.
The four quartile dose categories, ranging from quartile 1
(low dose) to quartile 4 (high dose). If any drug users had
had less than 2 years of statin, they were allocated to the
non-user group (n=556).
In the discrete time analysis, we wanted to assess change
in statin dose use in individual patients over time, and this
approach again incorporated ‘immortal’ time in which an
OA event might have occurred.30 Therefore, we split the
12 years into six 2-year time periods and summarised the
dose changes for each individual from the baseline 2-year
time period to each of the five respective follow-up time
windows. This approach resulted in four incremental dose
change groups, ranging from Group 1 (smallest dose
change) to Group 4 (largest dose change), with the pooled
estimate indicating that there was an increase in statin dose
of 3.61 mg every 2 years (also see Fig. 1).
Analysis
First, for the four mean daily dose quartile groups
compared to non-users, we estimated OA outcomes in
the 10-year follow-up period using Kaplan Meier plots.
Then, using Cox regression methods, with time to OA
event, we adjusted for age, gender, IMD status, BMI,
cholesterol level, other pain-modifying drug co-therapies
and duration and category of cardiovascular disease
group. Assumption of proportionality of hazard ratios
was tested throughout.
Second, using discrete time survival analysis, we wanted to
assess the influence of incremental changes in statin dose in
two shorter time periods of observation: (1) within each 2-year
time window and (2) a temporal 4-year approach. For within
each 2-year time period, we analysed the association between
changing statin dose and OA outcome, which means there
were six time windows. We then constructed a temporal
element by linking each initial 2-year time period with the
consecutive 2-year time period, to create five 4-year time
windows. In this ‘temporal approach’, each initial 2-year time
period was OA free, so that OA outcome was only assessed in
the subsequent 2-year window. Individual follow-up time was
first converted to 2-year blocks, and outcome and covariates
status were determined for each block. Discrete time survival
analysis was then used to model the risk of an OA event. This
method treats time not as a continuous variable, but as being
divided into discrete units. Within each time window, quartiles
of statin exposure were determined and used as a time varying
ordinal variable to reflect changing dose, which includes time
without possible statin exposure. Logistic regression methods
were used to compare changing dose groups with non-statin
users for OA outcomes for these shorter time frames, adjusting
for all covariates.
Finally, the statin analyses were repeated for each of the six
exclusive CVD subgroups, using the chi-square test for trend.
However, since the total number of statin users within each
CVD group was small, the study groups were categorised into
non-statin users, low dose statin users and high dose statin
users, using the mean daily dose per year estimates. Statistical
significance was defined as p<0.05, all hypothesis testing was
two-tailed, and analyses were performed using SPSS (version
18.0) and MLwiN (version 2.21).
RESULTS
Cohort Population
Within the overall study population, there were 4,976 statin
users who had been on at least 2 or more years of the statins
with an mean daily dose of 15 mg, and 11,633 non-statin
users (Table 1). Statins users were similar to non-users in
terms of age, deprivation, BMI and cholesterol characteris-
tics, but men were more likely to be on statins than women.
Of the statin users, there were higher proportions with
angina or myocardial infarction than non-users.
Statin Dose and OA Outcome
The mean quartile statin dose was as follows: quartile 1
(lowest dose), up to 5 mg daily; for quartile 2, up to 10 mg
daily; for quartile 3, up to 18 mg daily; and for quartile 4
(highest dose), over 18 mg daily. The associations between
statin dose quartiles and OA outcome in the follow-up
period are shown in Kaplan Meier plots (Fig. 2).Figure 1. Statin dose increments over the 10-year follow-up period.
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Over the 10-year follow-up period, higher mean daily
statin dose was significantly associated with a decreased
likelihood of clinical OA (Table 2), and the results showed
a dose-gradient response. Compared to statin non-users, the
relative adjusted estimates were as follows: quartile 1
(lowest dose), rate ratio 2.55 (95 % confidence interval
2.3–2.9); quartile 2, 1.31 (1.1–1.5); quartile 3, 0.82 (0.7–
0.95); and quartile 4 (highest dose), 0.41 (0.3–0.5). Older
age, female gender and higher BMI were significantly
associated with increased clinical OA outcome, but disease
categories, cholesterol levels, duration of disease and
specified drug co-therapies did not influence the likelihood
of clinical OA outcome.
Changing Statin Dose and OA Outcome
The influence of changing statin dose was also assessed for
its impact on OA outcome. In the 10-year follow-up period,
the 25th centile dose change was around 5 mg and the 75th
centile dose change was over 20 mg, as shown in Fig. 2.
First, in the six shorter within 2-year time windows,
larger dose change of statins was associated with a
reduction in clinical OA, again showing a dose-gradient
response (Table 3). Compared to statin non-users, the
adjusted (for age, gender, deprivation and drug co-thera-
pies) estimates were as follows: group 1 (smallest dose
increment): odds ratio 1.07 (95 % confidence interval 0.9–
1.3); group 2: 1.17 (0.9–1.4); group 3: 0.95 (0.8–1.2); and
group 4 (largest dose increment): 0.82 (0.7–0.99).
Second, in the temporal 4-year analyses, compared to
the statin non-users, the relative adjusted estimates were:
group 1 (smallest dose increment): odds ratio 1.7 (95 %
confidence interval 1.5–1.9); group 2: 0.98 (0.8–1.2);
group 3: 0.95 (0.8–1.1), and group 4 (largest dose
increment): 0.60 (0.5–0.7). At around 2 years, in the
group with the largest statin dose increment, there is a
Table 1. Characteristics of Statin Users and Non-Users Aged





Daily dose (SD) mg 14.6 (15.5) n/a
Age (SD) years 65 (9.6) 70 (13.1)
Men: Women 2,925:2,051 5,402:6,231
Deprivation (SD) 26 (19.2) 27 (19.3)
BMI kg/m2 (SD) 26 (5.1) 27 (5.1)
Cholesterol mmol/l (SD) 5.0 (0.9) 5.2 (1.2)
Hypertension† (%) 222 (4.5) 1,256 (11.3)
Atrial fibrillation† (%) 514 (10.3) 1,735 (15.7)
Angina† (%) 1,726 (34.7) 2,038 (18.4)
Myocardial infarction† (%) 1,410 (28.3) 1,166 (10.5)
Heart failure† (%) 265 (5.3) 2,096 (18.9)
Other cardiovascular
diagnosis† (%)
839 (16.9) 2,786 (25.2)
Antidepressants (%) 1,154 (23.2) 2,172 (19.6)
Non-opioids (%) 1,313 (26.4) 2,488 (22.5)
Non-steroidals (%) 2,923 (58.7) 5,305 (47.9)
Opioids (%) 2,292 (46.1) 4,346 (39.2)
Percentage figures (%) represent the statin users in 10-year follow-up
and non-users in the entire 12-year time period
*includes 556 statin users less than 2 years
†Exclusive diagnostic categories
Figure 2. Cumulative Kaplan-Meier plots for statin dose quartile groups and osteoarthritis (OA) outcome over 10-year follow-up.
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relative reduction estimated at 18 % in OA outcome
compared to non-statin users, and after 4 years, the
relative reduction was estimated at 40 %.
Statin Dose and OA Outcome by CVD
Severity
Within all the CVD subgroups, except heart failure, higher
dose of statin was associated with a reduction in clinical OA
outcome (Table 4). The statistically significant trends (p<
0.001) in the association between higher dose of statin and
reduction of OA outcome compared to non-statin users
were significant for atrial fibrillation, angina, myocardial
infarction, and ‘other’ CVD group.
DISCUSSION
Our study shows that increasing dose of statin use and larger
statin dose increments were associated with a reduction in
clinical OA compared to non-statin users. These findings were
not explained by the duration or severity of associated
cardiovascular disease, or pain-modifying drug co-therapies
or age, gender, deprivation, or baseline cholesterol levels or
BMI status. At the highest statin daily dose, which was a
therapeutic dose of around 20 mg daily, there was approxi-
mately a 60 % relative reduction in clinical OA outcome,
compared to non-statin users. Larger increments in the dose of
statins were also associated with a 40 % relative reduction in
clinical OA outcome compared to non-statin users over a 4-
year time period.
Table 2. Statin Dose Quartile Groups and Osteoarthritis (OA) Outcome Over 10-year Follow-Up
Factors Subgroups OA Estimates Rate ratio# (95 % CI)
Yes No β SE
Sociodemographic Older age 1,068 6,808 0.021 0.003 1.02 (1.01, 1.03)
Female 898 7,181 0.495 0.050 1.64 (1.5, 1.8)
Higher deprivation** 1,170 7,085 −0.001 0.001 1.00 (0.99, 1.01)
Higher body mass index†† 580 2,255 0.039 0.004 1.04 (1.0, 1.1)
Clinical status† Hypertension 155 1,323 n/a 1.0
Atrial fibrillation 314 1,940 0.040 0.139 1.04 (0.8, 1.4)
Angina 646 3,122 0.189 0.128 1.21 (0.94, 1.6)
Myocardial infarction 360 2,206 0.107 0.137 1.11 (0.9, 1.5)
Heart failure 202 2,168 −0·077 0.169 0.93 (0.7, 1.3)
Other CVD 583 3,050 0·085 0.134 1.09 (0.8, 1.4)
Longer disease duration††† 678 3,999 −0.007 0.008 0.99 (0.98, 1.0)
Higher cholesterol level†† 265 894 −0.091 0.027 0.91 (0.9,1.0)
Specific drug co-therapies‡ 1,438 8,050 0.085 0.049 1.09 (0.98, 1.2)
Statin dose None‡‡ 1,383 9,779 n/a 1.0
Quartile 1 (0.01–4.6 mg/day) 226 883 0.934 0.061 2.55 (2.3, 2.9)
Quartile 2 (4.7–9.9 mg/day) 274 881 0.266 0.70 1.31 (1.1, 1.5)
Quartile 3 (10.0–18.4 mg/day) 251 1,094 −0.204 0.076 0.82 (0.7, 0.95)
Quartile 4 (18.5 mg/day or more) 126 1,172 −0.889 0.100 0.41 (0.3, 0.5)
#Cox regression rate ratio adjusted for all co-variates
**Based on IMD, which is the Index of Multiple Deprivation, a census based area-level measure
†Patients with exclusive diagnostic categories in their clinical records for a 2-year time window (1995–1996)
‡Specific drug co-therapies relate to users of opioids, non-opioids, non-steroidal anti-inflammatories or anti-depressants in 2-year time windows
over the total 12 year period of observation
††Values refer to the first available recorded date in an individual’s clinical record and the (SD) summaries on available non-missing data
††includes 556 statin users less than 2 years
†††Time between age at first diagnosis and the date of diagnosis in the cohort sampling window
Table 3. Change in Statin Dose and Osteoarthritis (OA) Outcome: Discrete Time Series Designs








β SE β SE
None ref ref 1.0 ref ref 1.0
Group 1 (Smallest) 0.067 0.083 1.07 (0.9, 1.3) 0.531 0.058 1.7 (1.5, 1.9)
Group 2 0.154 0.087 1.17 (0.9, 1.4) −0.022 0.099 0.98 (0.8, 1.2)
Group 3 −0.046 0.106 0.95 (0.8, 1.2) −0.056 0.082 0.95 (0.8, 1.1)
Group 4 (Largest) −0.270 0.121 0.82 (0.7, 0.99) −0.516 0.111 0.60 (0.5, 0.7)
†Increasing dose change, as measured by mean dose in a 2-year time-block to subsequent 2-year time periods in the following 10 years
**Adjusted for all covariates: age, gender, deprivation, BMI, cholesterol level, specific drug co-therapies (opioids, non-opioids, non-steroidal anti-
inflammatories or antidepressants), and duration and diagnostic cardiovascular disease; specific drug co-therapies relate to users of opioids, non-
opioids, non-steroidal anti-inflammatories or antidepressants in 2-year time windows over the total 12-year period of observation
††Analyses applies to change in statin dose and OA event within the same 2-year time period, with estimates averaged for the five 2-year time
windows in the 10-year follow-up
†††Analyses applies to change in statin dose estimated from the prior 2-year time period, with OA event in the subsequent 2-year follow-up (therefore
again, five time windows, starting with 1995–1996 as the first window)
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Other emerging evidence over the life course is further adding
to idea of shared pathogenesis for OA and cardiovascular
disease. Studies have shown that the co-occurrence of OA and
cardiovascular disease is common.11,35,36 Severity of hand
osteoarthritis is associated with atherosclerosis37 and it has
also been shown that OA is a predictor of all-cause mortality,
particularly for cardiovascular disease-related mortality.38 An
additional relevant study suggests that diabetes, as part of the
metabolic syndrome, may influence the onset of OA.39
It is postulated that statin modification of OA might be
through two mechanisms, either through lowering of the
cholesterol levels5 or through anti-inflammatory properties.15
There is evidence of local inflammatory processes that occur
in osteoarthritis joints,40 and it is thought that traumatic stimuli
induce mechanical receptors in chondrocytes to produce
cytokines41 and matrix metalloproteinases, which lead to a
degradation of articular cartilage.42 Statins may modify these
inflammatory mechanisms, and this may be separate to that of
cholesterol lowering activity.
The study findings need to be placed within the context of
the design and measurement issues. Statins measurement was
based on prescribing by general practitioners, and in the
United Kingdom they are still clinician prescribed-only drugs.
This means the statin users and non-users were likely to be
clearly defined, and the construction of dose quartile groups
showed a gradient effect as hypothesised. The study design
time frame from 1995 to 2006, during which there was
increasing use of statins and statin doses, also provides the
appropriate cardiovascular population at risk for investigating
treatment hypothesis without indication.
The definition of OA was based on clinician-defined
diagnosis as presented by patients, and the study findings
for older age, female gender and body mass index
associations show the validity of such a definition. This
approach is reasonable, as in the UK it is largely presented
to and managed by GPs, and the population-based database
used has also been shown to have high clinical validity for a
range of clinical conditions.43 Finally, it is unlikely that
clinical recording of OA diagnostic labels would have been
influenced by statin prescribing, other than the random
variation in the recording of clinically defined OA, but the
large number of practices provide a reliable reflection of
clinical OA in the general population.
We also considered the potential effects of disease severity
and duration. Severity of cardiovascular disease may attenuate
the potential impact of statins, and the associations between
low dose statin groups and higher OA outcome compared to
reference group seemed to suggest this, but our study showed
that there was a gradient effect of statins within all but the heart
failure cohort. It is probable that the heart failure group
represents end-stage cardiovascular disease, when modifica-
tion of OA pathogenesis is too late to take effect. The
incorporation of duration of disease and statins modelled on
change in dose over time, also addressed the issue of
unexposed time, which can be an analytic bias30 in
pharmaco-epidemiology studies. An a priori treatment hy-
pothesis was tested, and even though there may still be
residual unmeasured confounders, it would be difficult to
propose alternative explanations of the dose response gradient
or the magnitude of statin effects that were shown.
CONCLUSIONS
This study provides evidence that therapeutic statin dose
and larger statin dose increments were associated with a
reduction in clinically defined OA outcome. These findings
further support the hypothesis that biologic modification of
OA may be plausible, and the potential clinical implication
is that OA management may share preventative approaches
with cardiovascular disease.
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Table 4. Statin Dose and OA Outcome over 10 year Follow up by
CVD Groups








Hypertension None 130 1,126 1.0
Low 15 96 0.91 (0.5, 1.8)
High 10 101 0.50 (0.3, 1.0)
Atrial Fibrillation None 214 1,521 1.0
Low 5 263 0.99 (0.7, 1.4)
High 12 234 0.69 (0.5, 1.0)
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Low 218 663 1.14 (0.9, 1.4)
High 108 737 0.49 (0.4, 0.6)
Myocardial
Infarction
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Low 115 578 1.36 (1.1, 1.8)
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Low 12 134 0.78 (0.4, 1.6)
High 20 99 0.93 (0.5, 1.7)
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to one of these was based on the most severe category; for example, if
an individual had consulted for hypertension and heart failure, they
would be classified into the heart failure category
*Statin dose summarised as mean daily dose
**Adjusted Cox regression rate ratios for all covariates: age, gender,
deprivation, BMI, cholesterol level, specific drug co-therapies (opi-
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